DK2070526T3 - Fremgangsmåder til behandling af parkinsons sygdom - Google Patents

Fremgangsmåder til behandling af parkinsons sygdom

Info

Publication number
DK2070526T3
DK2070526T3 DK09154864.4T DK09154864T DK2070526T3 DK 2070526 T3 DK2070526 T3 DK 2070526T3 DK 09154864 T DK09154864 T DK 09154864T DK 2070526 T3 DK2070526 T3 DK 2070526T3
Authority
DK
Denmark
Prior art keywords
disease
methods
treating parkinson
parkinson
treating
Prior art date
Application number
DK09154864.4T
Other languages
Danish (da)
English (en)
Inventor
Fariello Ruggero
Carlo Cattaneo
Patricia Salvati
Luca Benatti
Original Assignee
Newron Pharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33159845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2070526(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa
Application granted granted Critical
Publication of DK2070526T3 publication Critical patent/DK2070526T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK09154864.4T 2003-04-11 2004-04-08 Fremgangsmåder til behandling af parkinsons sygdom DK2070526T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46220503P 2003-04-11 2003-04-11
EP04726590A EP1613296B1 (en) 2003-04-11 2004-04-08 Methods for treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
DK2070526T3 true DK2070526T3 (da) 2014-03-24

Family

ID=33159845

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09154864.4T DK2070526T3 (da) 2003-04-11 2004-04-08 Fremgangsmåder til behandling af parkinsons sygdom
DK04726590T DK1613296T3 (da) 2003-04-11 2004-04-08 Fremgangsmåder til behandling af Parkinsons sygdom

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK04726590T DK1613296T3 (da) 2003-04-11 2004-04-08 Fremgangsmåder til behandling af Parkinsons sygdom

Country Status (28)

Country Link
US (3) US8283380B2 (enExample)
EP (2) EP2070526B1 (enExample)
JP (2) JP2006522800A (enExample)
KR (2) KR101129015B1 (enExample)
CN (2) CN1771030A (enExample)
AR (1) AR044007A1 (enExample)
AT (1) ATE435012T1 (enExample)
AU (1) AU2004228782B2 (enExample)
BR (1) BRPI0409364A (enExample)
CA (1) CA2523188C (enExample)
CY (3) CY1109295T1 (enExample)
DE (1) DE602004021790D1 (enExample)
DK (2) DK2070526T3 (enExample)
ES (2) ES2454272T3 (enExample)
FR (1) FR15C0054I2 (enExample)
HU (1) HUS1500043I1 (enExample)
IL (2) IL171331A (enExample)
LU (1) LU92782I2 (enExample)
MX (1) MXPA05010873A (enExample)
NL (1) NL300752I2 (enExample)
NO (3) NO334316B1 (enExample)
NZ (1) NZ542910A (enExample)
PL (2) PL1613296T3 (enExample)
PT (2) PT2070526E (enExample)
RU (1) RU2342929C2 (enExample)
SI (2) SI2070526T1 (enExample)
TW (1) TWI340640B (enExample)
WO (1) WO2004089353A2 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
IL160523A0 (en) 2001-09-03 2004-07-25 Newron Pharm Spa PHARMACEUTICAL COMPOSITION COMPRISING GABAPENTIN OR AN ANALOGUE THEREOF AND AN alpha-AMINOAMIDE AND ITS ANALGESIC USE
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
BRPI0413982A (pt) * 2003-08-25 2006-11-07 Newron Pharm Spa derivados de alfa-aminoamida úteis como agentes anti-inflamatórios
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
KR101277520B1 (ko) * 2004-09-10 2013-06-21 뉴론 파마슈티칼즈 에스. 피. 에이. （할로벤질옥시）벤질아미노－프로판아미드를 포함하는 선택적 나트륨 및／또는 칼슘 채널 조절제로서 유용한 약제학적 조성물
US20070004639A1 (en) * 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
US8772346B2 (en) 2005-11-09 2014-07-08 Torrent Pharmaceuticals Limited Pharmaceutical composition
HRP20160005T1 (hr) * 2005-12-22 2016-02-12 Newron Pharmaceuticals S.P.A. 2-feniletilamono derivati kao modulatori kalcijskih i/ili natrijskih kanala
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
US8106056B2 (en) * 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
JP5240476B2 (ja) 2006-06-19 2013-07-17 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー ２−［４−（３−及び２−フルオロベンジルオキシ）ベンジルアミノ］プロパンアミドの製造方法
DE102007014947B4 (de) * 2007-03-23 2010-05-27 Axxonis Pharma Ag Stabilisierte wässrige Lösungen von Ergolinverbindungen
US20100092554A1 (en) * 2007-04-24 2010-04-15 Boehringer Ingelheim International Gmbh Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
RS56780B1 (sr) 2007-06-15 2018-04-30 Newron Pharm Spa Substituisani derivati 2-[2-(fenil) etilamino]alkanamida i njihova upotreba kao modulatora kanala za natrijum i/ili kalcijum
GB2453770A (en) * 2007-10-19 2009-04-22 Reckitt Benckiser Healthcare Oral composition comprising a cooling agent
WO2009054964A1 (en) * 2007-10-22 2009-04-30 Concert Pharmaceuticals, Inc. Alpha-aminoamide derivatives
DK2229351T3 (en) 2007-12-11 2018-01-22 Newron Pharm Spa PROCEDURE FOR THE PREPARATION OF 2- [4- (3- OR 2-FLUORBENZYLOXY) BENZYLAMINO] PROPANAMIDS WITH HIGH PURITY
JP5736175B2 (ja) * 2007-12-19 2015-06-17 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー 精神障害の治療に有用なα−アミノアミド誘導体
WO2009122351A2 (en) * 2008-04-01 2009-10-08 Kangwon National University Anti-parkinsonian compounds mppe
CN102203053B (zh) * 2008-06-02 2015-11-25 基因里克斯(英国)有限公司 用于制备胺的改进方法
CN102123980B (zh) 2008-06-02 2014-05-07 基因里克斯(英国)有限公司 用于制备对映异构纯胺的方法
WO2009147681A1 (en) * 2008-06-06 2009-12-10 Pharma Two B Ltd. Pharmaceutical compositions for treatment of parkinson's disease
JP2011522892A (ja) * 2008-06-13 2011-08-04 テバ ファーマシューティカル インダストリーズ リミティド パーキンソン病緩和のためのラサギリン
WO2010010138A1 (en) * 2008-07-24 2010-01-28 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising pramipexole and a calcium channel blocker for the treatment of parkinson's disease
US20100189788A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
EP2218444A3 (en) * 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
EP2314569A1 (en) 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
CN102048717B (zh) * 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
WO2011098456A1 (en) * 2010-02-09 2011-08-18 Merck Serono S.A. Safinamide in the treatment of dyskinesia
SI2563355T1 (sl) 2010-04-27 2016-10-28 Newron Pharmaceuticals S.P.A. Postopek za izdelavo metansulfonatnih soli ralfinamida ali njihovih R-enantiomerov
EP2563347B1 (en) 2010-04-30 2016-10-12 Teikoku Pharma USA, Inc. Propynylaminoindan transdermal compositions
WO2012129429A2 (en) 2011-03-24 2012-09-27 Teikoku Pharma Usa, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
WO2013028639A1 (en) 2011-08-19 2013-02-28 The Trustees Of Princeton University C-halogen bond formation
US20150031768A1 (en) * 2011-08-19 2015-01-29 The Trustees Of Princeton University C-halogen bond formation
EP2776020B1 (en) 2011-11-09 2019-09-11 Teikoku Seiyaku Co., Ltd. Methods for the treatment of skin neoplasms
CN104884046A (zh) 2012-10-22 2015-09-02 丝维塔斯治疗公司 用于快速缓解帕金森病的左旋多巴制剂
KR20150059177A (ko) 2012-11-02 2015-05-29 테이코쿠 팔마 유에스에이, 인코포레이티드 프로피닐아미노인단 경피 조성물
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
JP2016523918A (ja) 2013-06-27 2016-08-12 シーダーズ−サイナイ メディカル センター 神経変性状態の予防および治療のためのアドレナリン受容体拮抗薬
MX2016013741A (es) * 2014-04-21 2017-04-06 Civitas Therapeutics Inc Rápido alivio de las fluctuaciones motoras en la enfermedad de parkinson.
PT3202759T (pt) 2014-10-02 2020-03-06 Megabiowood Co Ltd Derivado de alfa-aminoamida e composição farmacêutica contendo o mesmo
HRP20192250T1 (hr) * 2015-08-27 2020-05-15 Prexton Therapeutics Sa Derivat kromon oksima koji prodire u mozak za liječenje diskinezije uzrokovane levodopom
KR102889062B1 (ko) * 2016-03-17 2025-11-21 더 존스 홉킨스 유니버시티 Paris의 파네실화에 의해 파킨슨병을 예방 또는 치료하기 위한 방법
ITUA20163981A1 (it) 2016-05-31 2017-12-01 Zambon Spa Composizioni farmaceutiche comprendenti safinamide
WO2018132746A1 (en) * 2017-01-14 2018-07-19 Mischley Laurie Kathern Method of using human excrement and secretions for early detection of parkinson's disease
CN109251155A (zh) * 2017-07-14 2019-01-22 广东东阳光药业有限公司 α-氨基酰胺衍生物及其用途
WO2019036624A1 (en) * 2017-08-17 2019-02-21 Gu Zi Qiang MONOAMINE PAMOATE SALT TYPE ANTI-PARKINSON AGENTS, PROCESS FOR PREPARING AND USING SAME
WO2019086408A1 (en) 2017-11-02 2019-05-09 Zambon S.P.A. Pharmaceutical compositions comprising safinamide
KR102005019B1 (ko) * 2018-04-04 2019-07-31 한국과학기술연구원 뇌졸중의 예방 및 치료용 조성물
CN119587493A (zh) * 2019-09-12 2025-03-11 阿奇维生命科学公司 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物
LU101477B1 (en) * 2019-11-12 2021-05-14 Univ Luxembourg An inhibitor of an iron-containing hydrogenase of a methanogenic archaeon for use in the treatment or prevention of a parkinsonian condition
CN110938014A (zh) * 2019-11-28 2020-03-31 岳千奥 取代苯氧酰胺衍生物、应用及用于治疗帕金森病的药物
JP2023504876A (ja) * 2019-12-06 2023-02-07 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド 薬物組成物、キット及びその応用
CN110999980A (zh) * 2019-12-19 2020-04-14 新疆石河子职业技术学院（石河子市技工学校） 一种葡萄酒洗浸奶酪加工方法
JP2023538859A (ja) * 2020-08-31 2023-09-12 パーデュー、ファーマ、リミテッド、パートナーシップ レボドパ送達のための組成物及び方法
JP2024509888A (ja) * 2021-03-08 2024-03-05 プロシーナ バイオサイエンシーズ リミテッド パーキンソン病の治療
KR102790040B1 (ko) * 2021-06-24 2025-04-01 연세대학교 산학협력단 도파민 미모톱 기능 합성 펩티드 및 이를 포함하는 mao-b 억제제

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1140748A (en) 1966-06-23 1969-01-22 Ici Ltd New carboxylic acid derivatives
US3795739A (en) * 1972-02-14 1974-03-05 Hoffmann La Roche Treatment of parkinson disease
US4049663A (en) 1972-06-06 1977-09-20 Allen & Hanburys Limited Ethylene diamine derivatives
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4935429A (en) 1985-10-25 1990-06-19 Dackis Charles A Method of treating psychostimulant addiction
DE252290T1 (de) * 1986-06-10 1988-06-09 Chiesi Farmaceutici S.P.A., Parma Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
CA1336169C (en) 1988-03-01 1995-07-04 Walther Birkmayer Agent for treatment of parkinson's disease
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5502658A (en) 1990-12-27 1996-03-26 Relin; Arkadi Sampled-continuous probability method of velocity measurement of the object having informatively-structural inhomogeneity
GB9306886D0 (en) 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
US6258827B1 (en) * 1995-05-26 2001-07-10 Pfizer Inc. Combinations for the treatment of parkinsonism containing selective NMDA antagonists
GB9515412D0 (en) * 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20020019421A1 (en) * 2000-07-05 2002-02-14 Roni Biberman Compositions and therapy for substance addiction
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
FR2829027A1 (fr) * 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson

Also Published As

Publication number Publication date
AR044007A1 (es) 2005-08-24
SI1613296T1 (sl) 2009-10-31
AU2004228782A1 (en) 2004-10-21
CY2015025I1 (el) 2016-04-13
NO20054640L (no) 2005-12-09
US20070093495A1 (en) 2007-04-26
NZ542910A (en) 2007-10-26
EP2070526A1 (en) 2009-06-17
US20130053368A1 (en) 2013-02-28
NO20054640D0 (no) 2005-10-10
US9492410B2 (en) 2016-11-15
WO2004089353A2 (en) 2004-10-21
EP2070526B1 (en) 2014-02-26
RU2005131422A (ru) 2006-04-27
US8283380B2 (en) 2012-10-09
AU2004228782B2 (en) 2010-05-20
ES2454272T3 (es) 2014-04-10
US8901176B2 (en) 2014-12-02
LU92782I2 (fr) 2015-09-22
ES2326373T3 (es) 2009-10-08
PL1613296T3 (pl) 2009-12-31
EP1613296B1 (en) 2009-07-01
NO2015018I1 (no) 2015-08-03
WO2004089353A8 (en) 2005-09-01
TW200505423A (en) 2005-02-16
BRPI0409364A (pt) 2006-04-25
KR20060010745A (ko) 2006-02-02
CN102274517A (zh) 2011-12-14
DK1613296T3 (da) 2009-10-05
CN102274517B (zh) 2018-08-31
CN1771030A (zh) 2006-05-10
FR15C0054I2 (fr) 2018-01-26
WO2004089353A3 (en) 2004-12-16
NO2015018I2 (no) 2015-07-23
RU2342929C2 (ru) 2009-01-10
SI2070526T1 (sl) 2014-05-30
CA2523188A1 (en) 2004-10-21
PT2070526E (pt) 2014-03-31
IL171331A (en) 2012-03-29
CY2015025I2 (el) 2016-04-13
JP2013067647A (ja) 2013-04-18
TWI340640B (en) 2011-04-21
NO334316B1 (no) 2014-02-03
US20150150833A1 (en) 2015-06-04
MXPA05010873A (es) 2006-03-21
NO335537B1 (no) 2014-12-22
IL216403A (en) 2015-01-29
FR15C0054I1 (fr) 2015-11-09
EP1613296A2 (en) 2006-01-11
KR20110070929A (ko) 2011-06-24
PT1613296E (pt) 2009-07-30
JP2006522800A (ja) 2006-10-05
ATE435012T1 (de) 2009-07-15
HUS1500043I1 (hu) 2018-11-28
PL2070526T3 (pl) 2014-08-29
CA2523188C (en) 2012-09-25
CY1109295T1 (el) 2014-07-02
KR101129015B1 (ko) 2012-04-20
CY1115286T1 (el) 2017-01-04
DE602004021790D1 (de) 2009-08-13
IL216403A0 (en) 2011-12-29
NL300752I2 (enExample) 2016-07-05
NO20131417L (no) 2005-12-09

Similar Documents

Publication Publication Date Title
DK2070526T3 (da) Fremgangsmåder til behandling af parkinsons sygdom
DK1443955T3 (da) PDGF-BB til behandling af Parkinsons sygdom
DK1620437T3 (da) 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension
DE602004006169D1 (de) Substituierte 8'-pyri(mi)dinyl-dihydrospiro-äcycloalkylaminü-pyrimidoä1,2aüpyrimidin-6-onderivate
DK1720571T3 (da) Fremgangsmåde til behandling af hæmolytisk sygdom
DK1997512T3 (da) Fremgangsmåder til behandling af TWEAK-relaterede tilstande
DK2821085T3 (da) Rna-interferens til behandling af "gain-of-function"-forstyrrelser
DE602004019373D1 (de) Bilderzeugungsverfahren
DK1575597T3 (da) Anvendelse af rimexolon til behandling af öjentörhed
EP1664117A4 (en) IMMUNOGENIC
EP1611147A4 (en) 6 "amino-6" -DEOXYGALACTOSYLCERAMIDE
DE602004002056D1 (de) Fixation d'un coussin gonflable
DK1628988T3 (da) Hidtil ukendte 14- og 15 leddede ringforbindelser
EP1637883A4 (en) IMMUNOGROMATOGRAPHIC PROCESS
DE50207780D1 (de) Kalander
DK1639139T3 (da) Fremgangsmåder til påvisning af Alzheimers sygdom
FR2851326B3 (fr) Hotte d'extraction
DK1699747T3 (da) Fremgangsmåde til fremstilling af 2,3-cis-substitueret 2-arylpropenaler
DE602004030793D1 (de) Asynchrones flimmerreduktionsverfahren
FR2852042B1 (fr) Piece d'aretier
FR2892012B1 (fr) Procede d'epilation
DE50209339D1 (de) Kalander
ES1054316Y (es) "forjado nervado"
SE0201072D0 (sv) Homing process
NO20033536D0 (no) Snus-porsjonerer